Jobs / United States / Strand Therapeutics INC
Senior Scientist, RNA Process Sciences and Innovation
Strand Therapeutics INC · 🇺🇸 Boston, Massachusetts
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 8 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest May 2026) — the step every H-1B hire needs first. USCIS also records 1 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Strand Therapeutics INC paid sponsored hires in similar roles4 certified filings for “Scientist, LNP Discovery” (Biochemists and Biophysicists) in MA: $80k–$122k, median $80k. Most were filed at wage level I (75%) — 1 lottery entry, ≈15% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Strand Therapeutics INC
The US Department of Labor certified 8 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest May 2026) — the step every H-1B hire needs first. USCIS also records 1 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Strand Therapeutics INC →
About the role
Company Overview: Strand Therapeutics is a clinical-stage biotechnology company pioneering programmable mRNA therapeutics to unlock the full potential of genetic medicines. Strand is applying its proprietary Signal Stack platform, which integrates EverScript circular RNA, AmpliScript self-replicating RNA, SignalPath targeted delivery, and logic-driven SignalLock genetic circuits to enable precise control of therapeutic activity across tissues and cell types and overcome foundational limitations in targeting, durability, and safety. Strand is advancing a pipeline with an initial focus on oncology and autoimmune disease. Its initial program, STX-001, an intratumorally delivered LNP-encapsulated self-replicating RNA expressing IL-12, has demonstrated preliminary evidence of systemic immune activation and anti-tumor activity in patients with advanced solid tumors who have progressed on prior therapies. Building on this early clinical validation, intravenously delivered STX-003 is designed for tumor-targeted expression and avoidance of off-target expression. STX-003, which is expected to enter the clinic in mid-2026, has the potential to be a major step forward for the fields of genetic medicine and oncology. Strand is also advancing STX-005, an in vivo CAR-T program designed to enable controlled, durable expression and repeat dosing. Founded by MIT synthetic biology pioneers, Strand has raised over $250 million and is headquartered in Boston, MA. Become the next standout single strand! Job Summary: Strand is seeking a highly motivated and innovative Senior Scientist to join our Process Development team and lead Process Sciences & Innovation across our mRNA platforms. This role is intended for an experienced lab based technical leader who thrives on solving difficult problems, challenging conventional approaches, and identifying transformative technologies that can fundamentally improve how mRNA products are developed and manufactured. The successful candidate will bring deep expertise in mRNA process development, a strong understanding of emerging technologies, and a passion for translating novel ideas into practical solutions. Reporting to the Director of Process Development, this individual will serve as the technical lead for Process Sciences & Innovation, partnering closely with Analytical Development and Research, to identify, evaluate, and implement next-generation technologies that enhance process understanding, development efficiency, scalability, and product quality. The ideal candidate is an intellectually curious scientist who actively seeks out new ideas, remains at the forefront of advances in RNA therapeutics and bioprocessing, and is energized by bringing innovative technologies and concepts into practical application. This role will help shape the future direction of Strand’s mRNA development capabilities. Primary Responsibilities: • Own the technology scouting function for Process Development by identifying, evaluating, and championing emerging technologies that have the potential to transform mRNA development and manufacturing. • Design and execute experimental studies that challenge existing process paradigms and generate new approaches to mRNA synthesis and purification. • Partner closely with Analytical Development to develop and implement advanced characterization methods, process analytical technologies (PAT), in-line monitoring strategies, and real-time process understanding tools. • Evaluate emerging instrumentation, automation platforms, digital technologies, and data science approaches that can accelerate process development and improve manufacturing robustness. • Develop innovative strategies to improve process performance, scalability, reproducibility, and product quality across mRNA unit ope